The Journal of rheumatology · 1996
Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАПоддержка правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schnitz W, Taylor-Albert E, Targoff I N, Reichlin M, Scofield R H
Аннотация
OBJECTIVE: To characterize patients with anti-PM/Scl but no definite myositis-scleroderma (PM/SSc) overlap or either polymyositis/dermatomyositis (PM/DM) or systemic sclerosis (SSc) alone.
METHODS: Review of all patients with anti-PM/Scl identified at a reference serologic clinical laboratory.
RESULTS: We identified 5 patients with anti-PM/Scl not considered to have either PM, SSc, or PM/SSc. One had primary Sjögren's syndrome but the other 4 had some feature(s) of illness consistent with PM/DM or SSc, such as hypertensive crisis or interstitial lung disease. These 5 patients represented 10% of the total number of patients with anti-PM/Scl identified in our clinical laboratory.
CONCLUSION: Anti-PM/Scl may be a marker for atypical or subclinical presentations of the usually associated disease, or this autoantibody may precede expression of the underlying disease. The antibody may also be present in patients who never express PM, SSc, or PM/SSc. Anti-PM/Scl without the usually described illnesses is not uncommon in our series of 55 patients with anti-PM/Scl.
METHODS: Review of all patients with anti-PM/Scl identified at a reference serologic clinical laboratory.
RESULTS: We identified 5 patients with anti-PM/Scl not considered to have either PM, SSc, or PM/SSc. One had primary Sjögren's syndrome but the other 4 had some feature(s) of illness consistent with PM/DM or SSc, such as hypertensive crisis or interstitial lung disease. These 5 patients represented 10% of the total number of patients with anti-PM/Scl identified in our clinical laboratory.
CONCLUSION: Anti-PM/Scl may be a marker for atypical or subclinical presentations of the usually associated disease, or this autoantibody may precede expression of the underlying disease. The antibody may also be present in patients who never express PM, SSc, or PM/SSc. Anti-PM/Scl without the usually described illnesses is not uncommon in our series of 55 patients with anti-PM/Scl.